{"id":9665,"date":"2021-08-21T12:43:29","date_gmt":"2021-08-21T07:13:29","guid":{"rendered":"https:\/\/www.seminarsonly.com\/news\/?p=9665"},"modified":"2021-08-21T12:58:19","modified_gmt":"2021-08-21T07:28:19","slug":"dcgi-approval-for-zydus-cadilas-zycov-d-dna-based-vaccine-for-covid-19","status":"publish","type":"post","link":"https:\/\/seminarsonly.com\/news\/dcgi-approval-for-zydus-cadilas-zycov-d-dna-based-vaccine-for-covid-19\/","title":{"rendered":"DCGI Approval for Zydus Cadila’s ZyCoV-D : DNA-based vaccine for COVID-19"},"content":{"rendered":"

DCGI Approval for Zydus Cadila’s ZyCoV-D : DNA-based vaccine for COVID-19<\/span><\/h2>\n

India has approved a Zydus Cadila vaccine, ZyCoV-D, that can be given to all persons 12 years and older, including children. A statement has been issued by the Ministry of Science and Technology that Zydus Cadila has been approved by DCGI for urgent use with ZyCoV-D. “These were the first vaccines to be administered to all people including children and adults aged 12 and over in the world, indigenously-developed DNA-based vaccine COVID-19.” said the ministry.<\/p>\n

Zydus receives EUA from DCGI for ZyCoV-D, the only needle-free COVID vaccine in the world<\/span><\/h2>\n

Zydus Cadila is headquartered in Ahmedabad, India, and ranks 4th\u00a0in the Indian pharmaceutical industry. The group has manufacturing sites and research facilities spread across five states of Gujarat, Maharashtra, Goa, Himachal Pradesh and Sikkim in India and in the US and Brazil.<\/p>\n

Zydus\u2019 global business has a strong presence in the regulated markets of the US, Europe (France and Spain) and in the high profile markets of Latin America and South Africa. It is also present in a big way in 25 other emerging markets worldwide.<\/p>\n

Previously, the Central Drug Agency of India expert panel recommended that the three-dose “ZyCoV-D” vaccine from Zydus Cadila is taken in an emergency way.<\/p>\n

\"Zydus<\/p>\n

The Subject Expert Commission on Covid-19 of the Central Drug Standard Control Organization (CDSCO) on Thursday discussed the Zydus Cadila application and approved the emergency use of its coronavirus vaccine with a dose of three doses. recommended.<\/p>\n

The pharmaceutical company based in Ahmedabad requested DCGI for an emergency vaccine authorisation on 1 July. The enterprise said that the largest clinical trial in over 50 centres has been conducted so far.<\/p>\n

\n

Zydus Cadila receives approval for Emergency Use Authorization from DCGI for ZyCoV-D today. World\u2019s first & India\u2019s indigenously developed DNA based vaccine for #COVID<\/a>-19 to be administered in humans including children & adults 12 yrs and above: Ministry of Science & Technology pic.twitter.com\/VfL39B8xTJ<\/a><\/p>\n

\u2014 ANI (@ANI) August 20, 2021<\/a><\/p><\/blockquote>\n